Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$25.5 - $31.51 $10,710 - $13,234
420 Added 0.17%
251,288 $7.19 Million
Q1 2024

Apr 18, 2024

BUY
$27.7 - $35.48 $245,505 - $314,459
8,863 Added 3.66%
250,868 $7.33 Million
Q4 2023

Jan 16, 2024

BUY
$26.32 - $34.31 $1.57 Million - $2.04 Million
59,593 Added 32.67%
242,005 $8.17 Million
Q3 2023

Oct 11, 2023

BUY
$30.68 - $40.09 $118,946 - $155,428
3,877 Added 2.17%
182,412 $5.6 Million
Q2 2023

Jul 17, 2023

SELL
$36.12 - $47.5 $121,724 - $160,075
-3,370 Reduced 1.85%
178,535 $7.15 Million
Q1 2023

Apr 26, 2023

BUY
$35.53 - $43.38 $300,619 - $367,038
8,461 Added 4.88%
181,905 $7.42 Million
Q4 2022

Jan 27, 2023

SELL
$38.19 - $57.45 $325,493 - $489,646
-8,523 Reduced 4.68%
173,444 $6.7 Million
Q3 2022

Oct 11, 2022

SELL
$51.24 - $58.89 $67,124 - $77,145
-1,310 Reduced 0.71%
181,967 $9.68 Million
Q2 2022

Jul 19, 2022

SELL
$51.49 - $81.64 $269,292 - $426,977
-5,230 Reduced 2.77%
183,277 $10.7 Million
Q1 2022

Apr 22, 2022

BUY
$60.03 - $76.49 $558,279 - $711,357
9,300 Added 5.19%
188,507 $14.4 Million
Q4 2021

Jan 06, 2022

SELL
$47.97 - $62.21 $530,979 - $688,602
-11,069 Reduced 5.82%
179,207 $10.8 Million
Q3 2021

Oct 14, 2021

BUY
$54.64 - $61.3 $3.58 Million - $4.01 Million
65,442 Added 52.42%
190,276 $10.7 Million
Q2 2021

Jul 15, 2021

BUY
$59.18 - $69.99 $306,907 - $362,968
5,186 Added 4.33%
124,834 $7.58 Million
Q1 2021

Apr 20, 2021

SELL
$59.31 - $78.82 $1.84 Million - $2.44 Million
-30,963 Reduced 20.56%
119,648 $8.39 Million
Q4 2020

Jan 19, 2021

BUY
$50.47 - $66.26 $565,667 - $742,642
11,208 Added 8.04%
150,611 $9.01 Million
Q3 2020

Oct 13, 2020

BUY
$51.97 - $63.0 $7.24 Million - $8.78 Million
139,403 New
139,403 $8.38 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Tributary Capital Management, LLC Portfolio

Follow Tributary Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tributary Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tributary Capital Management, LLC with notifications on news.